A phase I/II study of an antitumor vaccination using alpha(1,3) galactosyltransferase expressing allogeneic tumor cells in patients with relapsed or refractory breast cancer.

Trial Profile

A phase I/II study of an antitumor vaccination using alpha(1,3) galactosyltransferase expressing allogeneic tumor cells in patients with relapsed or refractory breast cancer.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 07 Jul 2009

At a glance

  • Drugs Breast cancer vaccine (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Jul 2009 Primary endpoint identified as objective-clinical-response as reported by ClinicalTrials.gov.
    • 07 Jul 2009 Planned number of patients changed from 44 to 3 as reported by ClinicalTrials.gov.
    • 29 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top